Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

INTRODUCTION: Effective treatments for hormone-receptor-positive (HR(+)) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy are needed. Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data demonstrated that everolimus and exemestane...

Descripción completa

Detalles Bibliográficos
Autores principales: Yardley, Denise A., Noguchi, Shinzaburo, Pritchard, Kathleen I., Burris, Howard A., Baselga, José, Gnant, Michael, Hortobagyi, Gabriel N., Campone, Mario, Pistilli, Barbara, Piccart, Martine, Melichar, Bohuslav, Petrakova, Katarina, Arena, Francis P., Erdkamp, Frans, Harb, Wael A., Feng, Wentao, Cahana, Ayelet, Taran, Tetiana, Lebwohl, David, Rugo, Hope S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898123/
https://www.ncbi.nlm.nih.gov/pubmed/24158787
http://dx.doi.org/10.1007/s12325-013-0060-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898123/
https://www.ncbi.nlm.nih.gov/pubmed/24158787
http://dx.doi.org/10.1007/s12325-013-0060-1

Ejemplares similares